Your browser doesn't support javascript.
loading
Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany.
Tilch, Katharina; Hopff, Sina M; Appel, Katharina; Kraus, Monika; Lorenz-Depiereux, Bettina; Pilgram, Lisa; Anton, Gabi; Berger, Sarah; Geisler, Ramsia; Haas, Kirsten; Illig, Thomas; Krefting, Dagmar; Lorbeer, Roberto; Mitrov, Lazar; Muenchhoff, Maximilian; Nauck, Matthias; Pley, Christina; Reese, Jens-Peter; Rieg, Siegbert; Scherer, Margarete; Stecher, Melanie; Stellbrink, Christoph; Valentin, Heike; Winter, Christof; Witzenrath, Martin; Vehreschild, J Janne.
  • Tilch K; Faculty of Medicine, Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, University of Cologne, University Hospital Cologne, Cologne, Germany. tilch.katharina@gmail.com.
  • Hopff SM; Faculty of Medicine, Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, University of Cologne, University Hospital Cologne, Cologne, Germany.
  • Appel K; Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Kraus M; Helmholtz Center Munich, Institute of Epidemiology, Research Unit Molecular Epidemiology, Munich, Germany.
  • Lorenz-Depiereux B; German Center for Cardiovascular Research (DZHK), Partner Site Munich, Munich, Germany.
  • Pilgram L; Helmholtz Center Munich, Institute of Epidemiology, Research Unit Molecular Epidemiology, Munich, Germany.
  • Anton G; Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Berger S; Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Geisler R; Helmholtz Center Munich, Institute of Epidemiology, Research Unit Molecular Epidemiology, Munich, Germany.
  • Haas K; German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Illig T; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Berlin, Germany.
  • Krefting D; Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Lorbeer R; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Julius Maximilian University of Würzburg, Würzburg, Germany.
  • Mitrov L; University Hospital Würzburg, Institute for Medical Data Science (ImDS), Josef-Schneider Straße 2, 97080, Würzburg, Germany.
  • Muenchhoff M; Hannover Unified Biobank, Hannover Medical School, Hannover, Germany.
  • Nauck M; Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.
  • Pley C; German Center for Cardiovascular Research (DZHK), Partner Site Munich, Munich, Germany.
  • Reese JP; Deutsches Herzzentrum der Charité, Medical Heart Center of Charité and German Heart Institute Berlin, Institute of Computer-Assisted Cardiovascular Medicine, Berlin, Germany.
  • Rieg S; Department of Radiology, University Hospital LMU Munich, Munich, Germany.
  • Scherer M; Faculty of Medicine, Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, University of Cologne, University Hospital Cologne, Cologne, Germany.
  • Stecher M; German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Stellbrink C; Max Von Pettenkofer Institute & GeneCenter, Virology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany.
  • Valentin H; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Winter C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Berlin, Germany.
  • Witzenrath M; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Julius Maximilian University of Würzburg, Würzburg, Germany.
  • Vehreschild JJ; University Hospital Würzburg, Institute for Medical Data Science (ImDS), Josef-Schneider Straße 2, 97080, Würzburg, Germany.
BMC Med Ethics ; 24(1): 84, 2023 10 17.
Article en En | MEDLINE | ID: mdl-37848886
ABSTRACT
With the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global researchers were confronted with major challenges. The German National Pandemic Cohort Network (NAPKON) was launched in fall 2020 to effectively leverage resources and bundle research activities in the fight against the coronavirus disease 2019 (COVID-19) pandemic. We analyzed the setup phase of NAPKON as an example for multicenter studies in Germany, highlighting challenges and optimization potential in connecting 59 university and nonuniversity study sites. We examined the ethics application process of 121 ethics submissions considering durations, annotations, and outcomes. Study site activation and recruitment processes were investigated and related to the incidence of SARS-CoV-2 infections. For all initial ethics applications, the median time to a positive ethics vote was less than two weeks and 30 of these study sites (65%) joined NAPKON within less than three weeks each. Electronic instead of postal ethics submission (9.5 days (Q1 5.75, Q3 17) vs. 14 days (Q1 11, Q3 26), p value = 0.01) and adoption of the primary ethics vote significantly accelerated the ethics application process. Each study center enrolled a median of 37 patients during the 14-month observation period, with large differences depending on the health sector. We found a positive correlation between recruitment performance and COVID-19 incidence as well as hospitalization incidence. Our analysis highlighted the challenges and opportunities of the federated system in Germany. Digital ethics application tools, adoption of a primary ethics vote and standardized formal requirements lead to harmonized and thus faster study initiation processes during a pandemic.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans País como asunto: Europa Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans País como asunto: Europa Idioma: En Año: 2023 Tipo del documento: Article